Business Wire

Taiwan Donates Over 51 Million Masks to Countries Worldwide

22.7.2020 12:53:00 EEST | Business Wire | Press release

Share

As the COVID-19 pandemic ravages all parts of the world, Taiwan is lauded for donating over 51 million masks to more than 80 countries working to protect their people and especially front-line medical personnel from the virus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200722005405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vice Foreign Minister Miguel Li-jey Tsao (right) shook hands with Robert Seraki Matsebe, head of South Africa’s liaison office in Taipei on May 26, when 50,000 surgical masks were donated to the African republic. The masks would be distributed to doctors and nurses treating patients infected with the COVID-19 virus. (Photo: CNA Photo, courtesy of the Ministry of Foreign Affairs)

As of the end of June, recipients included the United States, Japan, Taiwan’s diplomatic allies, European Union members, other countries in Europe and nations in Southeast Asia and Latin America.

The donations were made in four rounds that began in April, when 10 million masks went to medical workers in the United States and 11 countries in Europe. In the third round, in which over seven million masks were donated in May, 600,000 went to Africa and the Middle East, including aid workers who have been caring for Syrian refugees.

Taiwan is able to help other countries because its government and people have worked together to contain the virus despite its close proximity to China, where the first COVID-19 cases were reported. As of July 21, Taiwan had reported 455 confirmed cases, including 364 imported ones. Only seven of those infected had died.

The island nation has increased its daily production of masks from 1.8 million in January to 20 million by the end of May by putting together a “national team” of machine tool manufacturers and mask makers.

When visiting a member company on the team, President Tsai Ing-wen said that reaching the goal of 20 million masks a day would help boost the morale of the country and prove that Taiwan could push the limits again and again.

There were no strings attached to the international aid, according to Joanne Ou, a spokeswoman for Taiwan’s Ministry of Foreign Affairs (MOFA).

“What Taiwan has done is merely give others a hand when it can manage to look after itself,” Ou told reporters on June 30. “What we’re doing is to fulfill our obligation as a country in the international community and we don’t seek reward or even expect public expressions of gratitude”

Thank-you messages have nonetheless come from all over the world. When Taiwan announced the first round of donations on April 1, American Institute in Taiwan Director William Brent Christensen, the de facto U.S. ambassador, expressed appreciation and called Taiwan “a real friend indeed.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Central News Agency
Name: 陳正杰 Jay Chen
Email: jenjey.chen@cna.com.tw
Phone: +886-2-25051180 ext. 100

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye